inhibition of pcsk9: the birth of a new...
TRANSCRIPT
![Page 1: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/1.jpg)
Inhibition of PCSK9:
The Birth of a New Therapy
Prof. John J.P. Kastelein, MD PhD FESC
Dept. of Vascular Medicine
Academic Medical Center / University of Amsterdam
The Netherlands
![Page 2: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/2.jpg)
2
Disclosures
Dr. Kastelein consults with and speaks for biotechnological
as well as pharmaceutical companies that develop
molecules that influence lipoprotein metabolism and / or
inflammation to prevend CVD, including Regeneron,
Sanofi, Amgen, Roche, Pfizer, and Eli Lilly
![Page 3: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/3.jpg)
3
Novel Approaches to Modify
Lipids and Lipoproteins
Low Density Lipoprotein
High Density Lipoprotein
Triglyceride Rich Lipoproteins
Inflammation
Lipoprotein a
![Page 4: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/4.jpg)
4
New Approaches to LDL Reduction
What is in development?
• Cholesterol Absorption Inhibitors
• Squalene Synthase (SSI) inhibitors
• Apo B mRNA antisense drugs
• Microsomal Triglyceride Transfer Protein (MTP) inhibitors
• Thyroxin Receptor Agonists
• PCSK9 Inhibitors
![Page 5: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/5.jpg)
5
LDL-Receptor Function and Life Cycle
![Page 6: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/6.jpg)
6
The Role of PCSK9 in the Regulation
of LDL Receptor Expression
![Page 7: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/7.jpg)
7
LDL-C Reduction and Coronary Events
Pro
po
rtio
na
l R
eductio
n in E
vents
Reduction in LDL-C (mmol/L)
Lancet 2005; 366: 1267–78
14 Trials
90,056
patients
![Page 8: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/8.jpg)
8
PCSK9 LOF Mutations
Adapted from Cohen JC. N Engl J Med 2006;354:1264-72; ARIC=Atherosclerosis Risk in the Community
30
20
10
0
PCSK9142x or PCSK9679X
No Yes
12
8
4
0
0 50 100 150 200 250 300
30
20
10
0
0 50 100 150 200 250 300
No Nonsense Mutation
(N=3278)50th Percentile
Plasma LDL Cholesterol in Black Subjects (mg/dL)
Fre
qu
en
cy (
%)
PCSK9142x or PCSK9679X
(N=85)
Co
ron
ary
He
art
Dis
ea
se
(%
)
88 percent reduction in the risk of CHD
28 percent reduction in frequency
![Page 9: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/9.jpg)
9
Loss of Function PCSK9 Mutations
Only a small number of patients who are homozygous (or compound heterozygotes) for PCSK9 have been discovered and studied.
These patients appear to have:
Very low LDL-C levels (~10-20 mg/dL)
Relatively low TG levels
Normal HDL-C levels
These patients have no other health problems
![Page 10: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/10.jpg)
10
Familial Hypercholesterolemia
![Page 11: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/11.jpg)
11
Familial Hypercholesterolemia
Mabuchi H et al. Circulation 1989;79:225–232.
![Page 12: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/12.jpg)
12
FH in the Netherlands:
Screening between January 1994 and December 2010
![Page 13: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/13.jpg)
13
FH in the Netherlands:
Screening between January 1994 and December 2010
![Page 14: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/14.jpg)
14
FH Patients at LDL Goal
![Page 15: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/15.jpg)
15
Impact of a SAR236553/REGN727
on LDL Receptor Expression
![Page 16: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/16.jpg)
16
The Use of a PCSK9 Monoclonal AB
in heFH Patients
A Randomized, Double-Blind, Placebo-Controlled Trial
of the Safety and Efficacy of a Monoclonal Antibody
to PCSK9, REGN727/SAR236553, in Patients with Heterozygous
Familial Hypercholesterolemia
on Stable Statin Dose With or Without Ezetimibe Therapy
Evan A. Stein, Dan Gipe, Jean Bergeron, Daniel Gaudet, Robert
Weiss, Robert Dufour, Richard Wu, Robert Pordy. Lancet, May 2012
![Page 17: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/17.jpg)
17
The Use of a PCSK9 Monoclonal AB
in heFH Patients
The goal of this Phase II trial was to evaluate the LDL-C efficacy and safety of REGN727/SAR236553 in:
o A larger population
o More diverse HeFH population in terms of LDLr defects
o More severely affected and aggressively treated group of HeFH patients, including those with CAD
o Assess multiple and higher doses combined with different dosing regimens of REGN727/SAR236553
![Page 18: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/18.jpg)
18
The Use of a PCSK9 Monoclonal AB
in heFH Patients
![Page 19: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/19.jpg)
19
The Use of a PCSK9 Monoclonal AB
in heFH Patients
![Page 20: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/20.jpg)
20
The Use of a PCSK9 Monoclonal AB
in heFH Patients: Results
![Page 21: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/21.jpg)
21
The Use of a PCSK9 Monoclonal AB
in heFH Patients: Results
![Page 22: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/22.jpg)
22
The Use of a PCSK9 Monoclonal AB
in heFH Patients: Goal Attainment
![Page 23: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/23.jpg)
23
The Use of a PCSK9 Monoclonal AB
in heFH Patients: Secondary Results
![Page 24: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/24.jpg)
24
The Use of a PCSK9 Monoclonal AB
in heFH Patients: Safety
![Page 25: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/25.jpg)
25
The Use of a PCSK9 Monoclonal AB
in Hypercholesterolemic Patients
![Page 26: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/26.jpg)
26
The Use of a PCSK9 Monoclonal AB
in Hypercholesterolemic Patients
Kohli P, et al. Clin Cardiol. 2012;35:385-391.
![Page 27: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/27.jpg)
27
The Use of a PCSK9 Monoclonal AB
in Hypercholesterolemic Patients: Results
![Page 28: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/28.jpg)
28
The Use of a PCSK9 Monoclonal AB
in Hypercholesterolemic Patients: Results
![Page 29: Inhibition of PCSK9: The Birth of a New Therapyassets.escardio.org/assets/Presentations/OTHER2013/Davos... · 2013. 3. 14. · to PCSK9, REGN727/SAR236553, in Patients with Heterozygous](https://reader031.vdocuments.us/reader031/viewer/2022013100/60a80b31c27a5415be21ba8e/html5/thumbnails/29.jpg)
29
Conclusion
In the next five years, we will prove or disprove that additional LDL lowering with other agents
than statins is effective
and
we will show or not show that the HDL hypothesis is true.